A study for a 40 year old woman who takes Zofran, Abilify - from FDA reports

65 females aged 40 (±5) who take the same drugs are studied. This is a personalized study for a 40 year old female patient who has Nausea And Vomiting, Depression. The study is created by eHealthMe based on reports from FDA.

How to use this study: bring a copy to your health teams to ensure drug risks and benefits are fully discussed and understood.

Who is eHealthMe: we are a data analysis company who specializes in health care industry. Our original studies have been referenced on 500+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and EANO. On eHealthMe, you can research drugs and monitor them (see testimonials). If you find eHealthMe useful, please help us to spread the words below or leave us a testimonial.

On Jul, 21, 2018

65 females aged 40 (±5) who take Zofran, Abilify are studied.

Number of reports submitted per year:

Zofran, Abilify for a 40-year old woman.

Information of the patient in this study:

  • Age: 40
  • Gender: female
  • Conditions: Nausea And Vomiting, Depression
  • Drugs taken:
    • Zofran (ondansetron hydrochloride)
    • Abilify (aripiprazole)

eHealthMe real world results:

Most common drug interactions over time

< 1 month:
  1. Memory loss
  2. Mania (a state of abnormally elevated or irritable mood)
  3. Pain
  4. Restless leg syndrome (a powerful urge to move your legs)
  5. Akathisia (a movement disorder characterized by a feeling of inner restlessness)
1 - 6 months:
  1. Burning mouth syndrome (pain in the mouth and burning sensation on tongue)
  2. Gallbladder operation
  3. Muscle spasms (muscle contraction)
  4. Abdominal pain upper
  5. Hypoaesthesia (reduced sense of touch or sensation)
6 - 12 months:
  1. Muscle spasms (muscle contraction)
  2. Gallbladder operation
  3. Hip joint replacement
  4. Abdominal pain upper
1 - 2 years:
2 - 5 years:
5 - 10 years:
  1. Weight decreased
  2. Dizziness
  3. Chest pain
  4. Balance disorder
  5. Fall
10+ years:
not specified:
  1. Swallowing pain or burning
  2. Pelvic pain
  3. Hypokalemia (low potassium)
  4. Uterine haemorrhage (uterine bleeding)
  5. Hepatic steatosis (fatty liver disease)

Top conditions involved for these people *:

  1. Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 19 people, 29.23%
  2. Metastases To Bone (cancer spreads to bone): 11 people, 16.92%
  3. Pain : 10 people, 15.38%
  4. Crohn's Disease (condition that causes inflammation of the gastrointestinal tract): 9 people, 13.85%
  5. Breast Cancer : 8 people, 12.31%

Top co-used drugs for these people *:

  1. Ativan (24 people, 36.92%)
  2. Protonix (22 people, 33.85%)
  3. Ambien (20 people, 30.77%)
  4. Lamictal (20 people, 30.77%)
  5. Xyrem (19 people, 29.23%)

* Some reports may have incomplete information.

FDA reports used in this study

You are not alone:

What are the drugs?

What are the conditions?

Related studies:

Related publications that referenced our studies

Recent updates

Recent general studies
Recent personal studies

NOTE: The study is based on active ingredients. Other drugs that have the same active ingredients are also considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Submit your testimonial

  • Please fill in your Testimonial.
  • Please enter a minimum of 10 characters for your Testimonial.
  • Please fill in your Name.

Please wait...


Thank you!